Atara Biotherapeutics (ATRA) Current Deferred Revenue (2020 - 2026)

Atara Biotherapeutics has reported Current Deferred Revenue for 7 years, with the latest figure at $684000.0 in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 95.72% year-over-year to $684000.0; the trailing twelve-month figure through Mar 2026 stood at $684000.0 (down 95.72% YoY), and the FY2025 full-year result was $716000.0, down 99.25% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $684000.0, down from $716000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $123.2 million in Q1 2024, with the low at $684000.0 in Q1 2026.
• Historically, Current Deferred Revenue has averaged $37.5 million across 5 years, with a median of $11.6 million in 2023.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue surged 1140.97% — and 2025, when it tumbled 99.25%.
• Atara Biotherapeutics' Current Deferred Revenue stood at $8.0 million in 2022, then jumped by 872.91% to $77.8 million in 2023, then increased by 22.17% to $95.1 million in 2024, then plunged by 99.25% to $716000.0 in 2025, then declined by 4.47% to $684000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $684000.0 (Q1 2026), $716000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.